Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 71.4%

Neg 0% Neu 71.4% Pos 0%

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.